Johnson & Johnson halted the limited rollout of its Varipulse pulsed field ablation system on Jan. 5 to “investigate the root causes of four reported neurovascular events in the U.S. external ...

Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA ...

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...

Johnson & Johnson said on Wednesday it temporarily paused the rollout of its Varipulse heart device in the United States as ...

Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

Johnson & Johnson shares are down 3% Wednesday on safety concerns that could dim sales prospects for a new heart device, ...

In that single-arm study, the rate of primary adverse events within 7 days of ablation was 2.9%, with the most common ...

Johnson & Johnson stock skidded Wednesday after the company temporarily paused sales of its pulsed field ablation system.

Johnson & Johnson said on Wednesday it has temporarily paused the rollout of its Varipulse heart device in the United States, ...

Piper Sandler analyst Matt O’Brien says Johnson & Johnson’s (JNJ) confirmation that it has temporarily paused the domestic launch of its ...

Johnson & Johnson MedTech announced that it has temporarily paused the United States External Evaluation and all United Stat ...

Johnson & Johnson announced that on January 5, “out of an abundance of caution,” Johnson & Johnson MedTech temporarily paused the U.S.